HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies (Q38444808)

3 September 2017

HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies (English)

1 reference

3 September 2017

anti-retroviral agent

0 references

author name string

Mark R Etherton

series ordinal

1

1 reference

PubMed ID

25916996

3 September 2017

Jennifer L Lyons

series ordinal

2

1 reference

PubMed ID

25916996

3 September 2017

Kevin L Ard

series ordinal

3

1 reference

3 September 2017

1 June 2015

1 reference

Current infectious disease reports

3 September 2017

1 reference

3 September 2017

17

1 reference

3 September 2017

6

1 reference

3 September 2017

485

1 reference

HIV-associated neurocognitive disorder.

3 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Updated research nosology for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Deficits in self-awareness impact the diagnosis of asymptomatic neurocognitive impairment in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

AIDS across Europe, 1994-98: the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

CSF penetration by antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Acute dystonia induced by lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Neuropsychiatric reaction induced by abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Drug points: Neuropsychiatric complications of nevirapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Exacerbation of depression associated with starting raltegravir: a report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Severe insomnia related to high concentrations of raltegravir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Antiretroviral neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-015-0485-6

Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity

21 January 2018

1 reference

12 December 2020

More on abacavir-induced neuropsychiatric reactions.

1 reference

12 December 2020

Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder

1 reference

12 December 2020

Cognitive dysfunction in HIV patients despite long-standing suppression of viremia

1 reference

12 December 2020

The relationship of CPE to HIV dementia: slain by an ugly fact?

1 reference

12 December 2020

Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.

1 reference

12 December 2020

Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands.

1 reference

12 December 2020

10.1007/S11908-015-0485-6

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

25916996